AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 52 min read$STOK

Ticho Barry sold $208K of STOK

Ticho Barry (CHIEF MEDICAL OFFICER) sold 7,176 shares of Stoke Therapeutics, Inc. (STOK) at an average of $29.04 ($28.95–$29.45, $0.21M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ticho Barry
Published Aug 5, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$STOK
Neutral
medium confidence
Mentioned
$STOK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STOKNeutralLow
01

Why it matters

The newest disclosed fact is the Aug 3 open-market sale by the company’s Chief Medical Officer, totaling about $208k, executed under a 10b5-1 plan.

02

Market read

For STOK, this is primarily a sentiment datapoint rather than a catalyst for fundamentals.

03

What to watch

Traders may overreact to insider selling without considering that the filing does not provide new information about pipeline, trial results, or financing.

Relevance 3/10Novelty 3/10Timing: filed Aug 5, covering Aug 3 insider sales

Background

The article is an SEC Form 4 insider transaction disclosure for Stoke Therapeutics, Inc. (STOK).

Company-level read

Ticker impact

$STOKNeutralMedium confidence
Context

Stoke Therapeutics disclosed via Form 4 that CMO Ticho Barry sold 7,176 shares in open-market transactions under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any move would be sentiment-driven rather than driven by new company fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and includes trade size, dates, and 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single insider sale at one biotech.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Stoke Therapeutics, Inc.

    Biopharma company whose insider transaction was disclosed on Form 4.

  • insider
    Ticho Barry

    Chief Medical Officer who sold 7,176 shares across two trades on Aug 3 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

STOK insider trading history →

Related articles

SEP 9
$STOKMedAI 8/10

Stoke Therapeutics at Cantor conference: dravet data, cash runway

Stoke Therapeutics (STOK) presented at the Cantor Fitzgerald conference, highlighting progress in its Phase III EMPEROR trial for Dravet syndrome, which completed enrollment ahead of schedule with 162 patients. The company expects top-line data in Q3 2027 and plans a rolling NDA submission in H1 2027. Stoke reported $400M in pro forma cash as of June 30, 2024, providing a runway through early 2028. Open-label extension data show a 75% sustained seizure reduction over four years. The stock traded

investing.com3 min
SEP 9
$STOKMedAI 8/10

STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones

Stoke Therapeutics (STOK) announced key milestones, including a phase III readout for Dravet syndrome within 12 months and progress in ADOA trials. Zorevunersen showed sustained 75% seizure reduction and functional gains, with long-term efficacy supported by OLE data. The EMPEROR study is well-powered, and the company's commercial strategy leverages robust clinical evidence.

tradingview.com1 min
SEP 4
$STOKMedAI 8/10

Stoke and Biogen report long-term zorevunersen Dravet data

Stoke Therapeutics and Biogen reported long-term data for zorevunersen, an investigational Dravet syndrome therapy, showing sustained seizure reductions and cognitive improvements over four years. The Phase 3 EMPEROR trial has completed enrollment, with data expected in Q3 2027 ahead of a planned U.S. NDA submission.

grafa.com1 min
SEP 4
$BIIBMedAI 8/10

Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrom

Stoke Therapeutics and Biogen presented long-term data at the 16th European Epilepsy Congress, showing zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a and OLE studies demonstrated durable seizure reductions, cognitive and behavioral improvements, and quality of life enhancements. The Phase 3 EMPEROR study data is expected in Q3 2027, aiming to complete the U.S. NDA submission. Zorevunersen was generally well tolerated, with some patients treated for over 5 years. Dravet synd

finanznachrichten.de2 min